Home > Insider Trading > Filing (0001104659-17-033537)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1641640	Nabriva Therapeutics Ag	NBRV	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1554194	Harrison George Talbot	1000 Continental Drive Suite 600 King Of Prussia PA 19406		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Shares	Acquisiton	2017-02-16	502	$0.00	3,351	No	4	M	Direct
Common Shares	Acquisiton	2017-02-16	155	$0.00	3,506	No	4	M	Direct
Common Shares	Acquisiton	2017-02-16	578	$0.00	4,084	No	4	M	Direct
Common Shares	Disposition	2017-05-15	50	$101.50	4,034	No	4	S	Direct
Common Shares	Disposition	2017-05-16	50	$102.27	3,984	No	4	S	Direct
Common Shares	Disposition	2017-05-16	100	$103.00	3,884	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Stock Option	Disposition	2017-02-16	502	$0.00	502	$0.00
Common Shares	Stock Option	Disposition	2017-02-16	155	$0.00	155	$0.00
Common Shares	Stock Option	Disposition	2017-02-16	578	$0.00	578	$0.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2017-09-27	No	4	M	Direct
0	2017-09-27	No	4	M	Direct
135	2017-09-27	No	4	M	Direct

Footnotes

This transaction is being reported late due to an administrative oversight.
The exercise price was Euro 6.72 per common share.
The common shares whose sale is reported on this line are represented by American Depositary Shares ("ADSs"). Each ADS represents one tenth (1/10) of a common share of Nabriva Therapeutics AG. The reporting person may hold both common shares and ADSs representing common shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of common shares.
The price of $101.50 per common share was derived from the sale price on May 15, 2017, of $10.15 per ADS, multiplied by ten.
The price of $102.268 per common share was derived from the sale price on May 16, 2017, of $10.2268 per ADS, multiplied by ten.
The price of $103.00 per common share was derived from the sale price on May 16, 2017, of $10.30 per ADS, multiplied by ten.
This option was granted on June 12, 2009 and is fully vested.
This option was granted on January 29, 2010 and is fully vested.
This option was granted on August 31, 2014. Vesting began on August 31, 2014 and ends on September 30, 2017. Twenty-five percent (25%) of the option vested on December 31, 2014, a further twenty-five percent (25%) of the options vested on December 31, 2015, and the remaining fifty percent (50%) vests on a monthly pro-rata basis over the remaining vesting period.